Budget Reductions Target FDA Field Operations
This article was originally published in The Tan Sheet
Executive Summary
President Obama’s fiscal 2016 budget request includes cuts to “low priority” enforcement, surveillance and other activities in the FDA human drugs and biologics programs, but still increases drug and biologics program budgets overall.
You may also be interested in...
Priority Review Vouchers Could Be Used Frequently Next Year
FDA requests enough pediatric rare disease priority review voucher user fees to fund three redemptions in fiscal year 2016.
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
CDER’s Woodcock says the new database will drive risk-based inspection decisions.
FDA Could Release GMP Data To Prod Manufacturing Improvements
Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.